Table 3 Specific characteristics of bottom-up studies and results of composite analysis
From: The global economic burden of COVID-19 disease: a comprehensive systematic review and meta-analysis
Study | Country | Sample size | Direct medical cost (mean, $US PPP*) | Direct nonmedical cost (mean, $US PPP*) | Indirect cost (mean, $US PPP*) |
|---|---|---|---|---|---|
Jeck et al. (2021) [18] | Germany | 105 | 25,244 | - | - |
Kotwani et al. (2021) [19] | India | 138 | 1264 | 25 | 187 |
Tsai et al. (2021) [20] | USA | 268,706 | 21,752 | - | - |
Nguyen et al. (2021) [35] | USA | 17,456 | 54,156 | - | - |
Weiner et al. (2021) [21] | USA | 1,470,721 | 1701 | - | - |
Fusco et al. (2021) [22] | USA | 173,942 | 24,571 | - | - |
Edoka et al. (2021) [23] | South Africa | NA | 1908 | - | - |
Tabuñar et al. (2021) [24] | Philippines | 691 | 12,236 | - | - |
Zhao et al. (2021) [25] | China | 100 | 79,315 | - | - |
Maltezou et al. (2021) [10] | Greece | 254 | 1571 | - | 4025 |
Ghaffari Darab et al. (2021) [43] | Iran | 477 | 3755 | - | 4145 |
Barasa et al. (2021) [27] | Kenya | NA | 4293 | - | - |
Seon et al. (2021) [28] | South Korea | 7969 | 7814 | - | - |
Banke-Thomas et al. (2021) [29] | Nigeria | 9 | 2551 | 71 | 1144 |
Li et al. (2020) [30] | China | 70 | 11,256 | ||
Jin et al. (2020) [7] | China | 81,879/915,824 | 5264 | - | 689,556 |
Kirigia et al. (2020) [31] | China | 2595 | - | - | 587,290 |
Lee et al. (2020) [32] | South Korea | 145 | 3002 | - | - |
Khan et al. (2020) [33] | Kingdom of Saudi Arabia | 1422 | 30,021 | - | - |
Romero et al. (2020) [34] | Spain | 198 | 2258 | - | - |